

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EL 820011415 US
Express Mail Label NumberApril 30, 2002
Date of Deposit

RECEIVED

JUL 1 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

BRAIN ET AL.

APPLICATION NO: 10/009,009

FILED: DECEMBER 3, 2001

FOR: BRADYKININ RECEPTOR ANTAGONISTS

05/08/2002 SNAJARRO 00000061 190134 10009009
01 FC:154 130.00 CH**Attention: Box Missing Parts**
Assistant Commissioner for Patents
Washington, DC 20231RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371

Sir:

The Notification of Missing requirements under 35 U.S.C. 371 (a copy of which is enclosed) has a shortened statutory time set to expire on June 8, 2002.


In response, applicants submit that an original declaration was filed with the United States designated Office on December 20, 2001. A copy of the Transmittal Letter and a copy of the fully executed Declaration and Power of Attorney are enclosed herewith. Also enclosed is the stamped postcard showing that the signed declaration was received at the PCT/PTO on December 20, 2001.

The requirement for a copy of the "Sequence Listing" in computer readable form is believed to be in error. The instant application does not contain a nucleotide and/or amino acid sequence as defined in 37 CFR 1.821. Accordingly, applicants are not submitting one. If the requirement still stands, applicants respectfully request that the particular amino acid and/or nucleotide sequence for which the "Sequence Listing" is required be specifically pointed out.

In view of the foregoing, it is believed that no fee is due. However, the Commissioner is hereby authorized to charge any fees which may be required to Deposit Account No. 19-0134 in the name of Novartis Corporation.

Respectfully submitted,

Novartis Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6932
Date: April 30, 2002


Carol A. Loeschorn
Attorney for Applicants
Reg. No. 35,590

Encl: as noted